2 430

Cited 25 times in

Chronic Pseudomonas aeruginosa infection in cystic fibrosis airway disease: metabolic changes that unravel novel drug targets

DC Field Value Language
dc.contributor.author윤상선-
dc.date.accessioned2015-07-14T16:35:23Z-
dc.date.available2015-07-14T16:35:23Z-
dc.date.issued2004-
dc.identifier.issn1478-7210-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/111195-
dc.description.abstractThe cystic fibrosis (CF) airways have an incompletely characterized defect in innate defense that eventually leads to bacterial infection and airway inflammation. Persistent Pseudomonas aerugionsa infection resulting from defective innate immunity and a bacterial phenotypic switch to a more intractable mucoid form inside the airway are now well established as important components of CF pathogenesis. Broad-based factors leading to chronic infection will be discussed with respect to: bacterial virulence in the context of biofilm formation, quorum sensing machinery and alginate overproduction, and failure of innate lung immunity in CF airways. In addition, a controversial question as to whether inflammation or infection comes first during CF airway disease will be addressed. Finally, a new hypothesis, that P. aeruginosa thrives as biofilms within the thickened anaerobic mucus layers, will be developed.-
dc.description.statementOfResponsibilityopen-
dc.format.extent611~623-
dc.relation.isPartOfEXPERT REVIEW OF ANTI-INFECTIVE THERAPY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAnimals-
dc.subject.MESHAnti-Bacterial Agents/therapeutic use-
dc.subject.MESHBiofilms-
dc.subject.MESHChild-
dc.subject.MESHChronicDisease-
dc.subject.MESHCysticFibrosis/complications*-
dc.subject.MESHCysticFibrosis/drugtherapy-
dc.subject.MESHCysticFibrosis/metabolism-
dc.subject.MESHCysticFibrosis/pathology-
dc.subject.MESHCysticFibrosis/physiopathology-
dc.subject.MESHHumans-
dc.subject.MESHInflammation/pathology-
dc.subject.MESHMice-
dc.subject.MESHMucus/physiology-
dc.subject.MESHPseudomonasInfections/complications*-
dc.subject.MESHPseudomonasInfections/drugtherapy-
dc.subject.MESHPseudomonasInfections/metabolism-
dc.subject.MESHPseudomonasaeruginosa/drugeffects-
dc.subject.MESHPseudomonasaeruginosa/genetics-
dc.subject.MESHPseudomonasaeruginosa/physiology-
dc.titleChronic Pseudomonas aeruginosa infection in cystic fibrosis airway disease: metabolic changes that unravel novel drug targets-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Microbiology (미생물학)-
dc.contributor.googleauthorSang Sun Yoon-
dc.contributor.googleauthorDaniel J Hassett-
dc.identifier.doi10.1586/14787210.2.4.611-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA02558-
dc.relation.journalcodeJ00878-
dc.identifier.eissn1744-8336-
dc.identifier.pmid15482224-
dc.identifier.urlhttp://informahealthcare.com/doi/abs/10.1586/14787210.2.4.611-
dc.subject.keywordalginate production-
dc.subject.keywordanaerobic metabolism-
dc.subject.keywordbiofilms-
dc.subject.keywordcystic fibrosis-
dc.subject.keywordmucociliary clearance-
dc.subject.keywordPseudomonas aeruginosa-
dc.subject.keywordquorum sensing-
dc.contributor.alternativeNameYoon, Sang Sun-
dc.contributor.affiliatedAuthorYoon, Sang Sun-
dc.rights.accessRightsnot free-
dc.citation.volume2-
dc.citation.number4-
dc.citation.startPage611-
dc.citation.endPage623-
dc.identifier.bibliographicCitationEXPERT REVIEW OF ANTI-INFECTIVE THERAPY, Vol.2(4) : 611-623, 2004-
dc.identifier.rimsid36200-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Microbiology (미생물학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.